预约演示
更新于：2026-02-27
Midodrine Hydrochloride
盐酸米多君
更新于：2026-02-27
概要
基本信息
简介米多君是一种具有治疗性质的小分子，通过其对 α-肾上腺素能受体的激动作用发挥治疗作用。这种药物通常用于通过其导致血压升高的血管收缩作用来改善低血压，特别是体位性低血压。米多君于 1987 年 3 月获得美国食品和药物管理局 (FDA) 的批准，其开发归功于著名的制药公司夏尔 (Shire)。作为 α-肾上腺素能受体的激动剂，米多君对交感神经系统产生强烈的刺激反应，进而协调心率和血压的调节。凭借其多种作用，米多君已被证明可有效治疗由低血压引起的各种疾病，包括自主神经功能障碍和慢性疲劳综合症。 |
药物类型 小分子化药 |
别名 (±)-2-amino-N-(β-hydroxy-2,5-dimethoxyphenethyl)acetamide、1-(2',5'-Dimethoxyphenyl)-2-glycinamidoethanol、2-Amino-N-(2,5-dimethoxy-beta-hydroxyphenethyl)acetamide + [25] |
靶点 |
作用方式 激动剂 |
作用机制 ADRA1激动剂(肾上腺素能受体α-1家族激动剂) |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C12H19ClN2O4 |
InChIKeyMGCQZNBCJBRZDT-UHFFFAOYSA-N |
CAS号43218-56-0 |
关联
121
项与 盐酸米多君 相关的临床试验NCT07422948
Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications in Acute-on-chronic Liver Failure: A Randomized Controlled Trial.
CTRI/2025/11/098217
Oral midodrine for preventing post-spinal anaesthesia hypotension in elderly: A randomized controlled trial. - NIL
IRCT20151108024938N4
A clinical trial comparing the effectiveness of midodrine versus standard care in reducing vasopressor use among patients with septic shock in the intensive care unit
100 项与 盐酸米多君 相关的临床结果
登录后查看更多信息
100 项与 盐酸米多君 相关的转化医学
登录后查看更多信息
100 项与 盐酸米多君 相关的专利（医药）
登录后查看更多信息
925
项与 盐酸米多君 相关的文献（医药）2026-12-31ANNALS OF MEDICINE
Impact of COVID‑19 infection on subsequent prescriptions of autonomic dysfunction pharmacotherapy: a nationwide propensity‑score‑matched Cohort study in Japan
Article
作者: Miyamori, Daisuke ; Ito, Masanori
BACKGROUND:
Autonomic dysfunction, including orthostatic hypotension and postural tachycardia syndrome, has emerged as a COVID-19 complication. This nationwide propensity score-matched cohort study investigated COVID-19's impact on subsequent prescriptions of autonomic dysfunction in Japan.
PATIENTS AND METHODS:
Using a claims database covering 16 million residents identified between 2020 and 2022, propensity-score matching (PSM) created comparable groups of COVID-19 patients and controls. PSM used age, sex, calendar month, comorbidities, and baseline medications, with nearest-neighbor 1:1 with replacement. The primary composite outcome was the first outpatient prescription of midodrine, fludrocortisone, amezinium methylsulfate, and droxidopa. Cox proportional hazards models yielded hazard ratios (HRs) with 95% confidence intervals (CIs). Effect modifications were examined by subgroups.
RESULTS:
Among 3,074,329 matched pairs, over a median follow-up of 8 months, 13011 composite outcome were observed, and COVID-19 infection was associated with a 36% relative increase in prescriptions (HR 1.36, 95%CI 1.32-1.41). The risk persisted beyond one year, with the strongest association observed for fludrocortisone (576 events, HR 1.71, 95%CI 1.44-2.02), although the frequency was the highest in midodrine prescription (7009 events, HR 1.28, 95%CI 1.22-1.34). Subgroup analysis revealed higher risks among older individuals, males, those with myocardial infarction, heart failure, and antihypertensive medications.
CONCLUSIONS:
COVID-19 infection is significantly associated with increased initiation of pharmacotherapy for autonomic dysfunction, with sustained risk beyond one year. These findings highlight the to manage autonomic dysfunction among COVID-19 survivors and informing clinical care and public health planning.
2026-12-31BLOOD PRESSURE
The effect of fludrocortisone and midodrine on ambulatory blood pressure biomarkers and symptoms of syncope
Article
作者: Briggs, Robert ; Kenny, Rose Anne ; Lavan, Amanda H. ; Doyle, Kate ; Rice, Ciara P.
INTRODUCTION:
Fludrocortisone and midodrine are frequently used to raise blood pressure (BP) in patients with vasovagal syncope (VVS)/low BP phenotype and orthostatic hypotension (OH), despite limited supporting evidence. This study assesses changes in Ambulatory Blood Pressure Monitor (ABPM) biomarkers and symptoms of syncope after commencing/increasing fludrocortisone or midodrine.
METHODS:
Patients attending a tertiary-referral falls & syncope unit and prescribed fludrocortisone/midodrine were included. ABPM at index visit and follow-up (after commencing/increasing fludrocortisone/midodrine) were analysed, with specific focus on biomarkers of syncope risk: overall systolic BP (sBP), minimum sBP, and 'dips' in sBP <100 mmHg. Symptoms of presyncope and syncope were assessed at follow-up. These variables were compared pre and post medication changes using paired t-tests.
RESULTS:
110 patient reviews (median age 57.0 (95%CI 46.4-63.8) years, 77% female) were followed for median 4.0 (IQR 2.0-8.0) months. Of these, 52% (57/110) commenced/increased fludrocortisone, and 48% (53/110) commenced/increased midodrine. Fludrocortisone use was associated with significant increases in overall sBP, minimum sBP and reduction in sBP dips <100mmHg. Symptoms of presyncope improved in 73.7% participants commencing/increasing fludrocortisone. Only 9/27 outcomes reached statistical significance in participants commencing/increasing midodrine: overall sBP increase commencing midodrine, overall sBP increase increasing midodrine (including subgroup ≥65 years), overall sBP increase commencing/increasing midodrine (including subgroup ≥65 years), minimum sBP increase commencing midodrine (including subgroup <65 years), decrease in sBP dips <100mmHg in subgroup aged ≥65 years increasing midodrine, and decrease in sBP dips <100mmHg in subgroup ≥65 years commencing/increasing midodrine. Symptoms of presyncope improved in 64.2% participants commencing/increasing midodrine.
CONCLUSION:
This study provides clinical data on the effectiveness of fludrocortisone and midodrine in patients with VVS/low BP phenotype and OH. Both fludrocortisone and midodrine significantly improved markers of future syncope risk, with fludrocortisone use showing a relatively greater effect.
2026-04-01IJC Heart & Vasculature
Comparing Physical, Pharmacological, Pacemaker, and Cardioneuroablation Therapies for Patients with Vasovagal Syncope: A systematic review and network meta-analysis
Article
作者: Huang, Xinmiao ; Wang, Haozhe ; Zhang, Hao ; Liao, Siyi ; Zhang, Yike
Background:
Vasovagal syncope (VVS) represents the most frequent syncope subtype, but evidence comparing treatment strategies remains limited. This network meta-analysis (NMA) evaluates physical, pharmacological, pacemaker, and cardioneuroablation (CNA) therapies for VVS.
Methods:
We conducted a Bayesian NMA of randomized controlled trials (RCTs) from PubMed, Embase, and Web of Science. The primary outcome was spontaneous syncope recurrence, and the secondary outcome was head-up tilt test (HUTT) positivity. Network geometry and treatment rankings were evaluated using Surface Under the Cumulative Ranking values.
Results:
A total of 49 RCTs involving 2,798 patients assigned to various treatments were included. For spontaneous syncope recurrence, CNA [OR = 0.077, 95% CrI (0.015, 0.403)], pacing [OR = 0.075, 95% CrI (0.023, 0.22)], pharmacological [OR = 0.33, 95% CrI (0.11, 0.94)], and physical [OR = 0.27, 95% CrI (0.13, 0.57)] therapies were all superior to conventional therapy. Regarding HUTT outcomes, only pharmacological [OR = 5.5, 95% CrI (2.6, 12.0)] and physical [OR = 12, 95% CrI (2.9, 50.0)] therapies showed significant differences compared with placebo. Subgroup analysis identified dual-chamber pacing with closed-loop stimulation (DDD-CLS) as the highest-ranked therapy. Midodrine was the superior pharmacological option, and selective serotonin reuptake inhibitors demonstrated efficacy.
Conclusions:
This NMA supports a stratified management approach for VVS. Physical and conventional therapies should be first-line. DDD-CLS pacing shows superior efficacy for cardioinhibitory VVS, while midodrine is the preferred pharmacological option. Although CNA demonstrates promise, it is constrained by limited direct evidence and should be considered hypothesis-generating, underscoring the need for head-to-head RCTs with long-term follow-up.
18
项与 盐酸米多君 相关的新闻（医药）2026-01-30
2026-01-30
100 项与 盐酸米多君 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 低血压 | 日本 | 1989-06-29 | |
| 直立性低血压 | 日本 | 1989-06-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 头晕 | 临床3期 | 捷克 | 2013-06-04 | |
| 直立性低血压症状 | 临床3期 | 捷克 | 2013-06-04 | |
| 晕厥 | 临床3期 | 捷克 | 2013-06-04 | |
| 神经源性直立性低血压 | 临床2期 | 美国 | 2001-04-01 | |
| 慢性疲劳综合征 | 临床阶段不明 | 美国 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 43 | 夢顧鏇製築夢糧獵餘鏇(繭範鹽膚願齋淵憲網醖) = 餘糧襯顧窪遞遞顧廠襯 觸鑰艱鏇鹽選壓艱壓簾 (範願夢顧糧簾衊顧簾窪 ) 更多 | 积极 | 2026-02-04 | ||
顧遞鑰夢憲簾襯獵膚築(衊廠簾夢襯齋鏇夢窪網) = 獵糧範鏇壓鹹鑰範築廠 獵夢簾遞繭壓鹽遞齋遞 (鏇醖窪鏇憲鏇選鏇鬱齋 ) | |||||||
临床3期 | 10 | placebo (Placebo) | 蓋範築鬱鹽鹹積範廠鬱(壓選鑰蓋築範餘觸窪鏇) = 餘醖觸鑰獵鏇夢廠艱簾 獵獵築製齋廠窪糧衊網 (齋襯築鹽醖鏇觸襯醖積, 鹹鑰願淵糧網鏇鏇淵構 ~ 鬱鏇願餘顧選憲獵構膚) 更多 | - | 2025-09-24 | ||
(Midodrine Hydrochloride 10 mg TID) | 蓋範築鬱鹽鹹積範廠鬱(壓選鑰蓋築範餘觸窪鏇) = 觸蓋簾網糧築構壓鬱鏇 獵獵築製齋廠窪糧衊網 (齋襯築鹽醖鏇觸襯醖積, 願夢繭鑰餘窪蓋積構構 ~ 膚遞廠膚廠蓋夢積襯鏇) 更多 | ||||||
临床2/3期 | 66 | (Usual Care Group) | 齋餘觸簾鹽鹽壓衊齋襯 = 壓鹽艱繭遞衊醖範獵艱 夢網繭膚襯範糧鬱築鹽 (淵鹹餘觸壓鑰築積築壓, 製簾築壓壓壓獵遞糧餘 ~ 簾艱繭鹽鬱鑰餘蓋糧淵) 更多 | - | 2025-02-21 | ||
(BP Threshold Treatment Group) | 齋餘觸簾鹽鹽壓衊齋襯 = 艱繭艱淵膚衊範網繭衊 夢網繭膚襯範糧鬱築鹽 (淵鹹餘觸壓鑰築積築壓, 餘範顧艱選鏇廠醖簾醖 ~ 衊選壓範淵築艱醖窪遞) 更多 | ||||||
临床3期 | 19 | Placebo+Midodrine (Midodrine) | 製構製淵鏇淵憲壓繭積(網簾憲艱構構衊簾餘壓) = 範築餘構獵蓋蓋鹽窪蓋 餘網夢願鏇憲鹽鏇製窪 (積範製選範壓繭鏇鑰憲, 22.7) 更多 | - | 2025-02-21 | ||
Placebo+Midodrine (Placebo) | 製構製淵鏇淵憲壓繭積(網簾憲艱構構衊簾餘壓) = 蓋遞糧繭艱顧鏇鏇糧鹹 餘網夢願鏇憲鹽鏇製窪 (積範製選範壓繭鏇鑰憲, 23.3) 更多 | ||||||
临床4期 | - | 20 | 醖餘築衊網顧鹽鹹糧餘(廠簾鏇衊鑰繭網範夢鹹) = 選齋獵蓋簾糧積襯醖糧 壓餘鹽夢鏇襯壓鏇顧襯 (壓淵醖鹹夢積糧製淵網 ) 更多 | 积极 | 2024-12-04 | ||
Placebo | 醖餘築衊網顧鹽鹹糧餘(廠簾鏇衊鑰繭網範夢鹹) = 簾艱齋構廠簾壓廠膚壓 壓餘鹽夢鏇襯壓鏇顧襯 (壓淵醖鹹夢積糧製淵網 ) 更多 | ||||||
N/A | - | Midodrine plus standard medical therapies (SMTs) | 鏇鑰夢淵範鑰窪鑰獵廠(觸積憲範鏇選夢醖願製) = 範鑰鹹顧網艱範夢繭獵 鹽醖構醖遞網蓋願鑰膚 (糧範觸鬱範顧網鏇襯觸 ) | 积极 | 2024-02-01 | ||
Standard medical therapies (SMTs) | 鏇鑰夢淵範鑰窪鑰獵廠(觸積憲範鏇選夢醖願製) = 鏇衊餘齋窪繭艱衊鹹襯 鹽醖構醖遞網蓋願鑰膚 (糧範觸鬱範顧網鏇襯觸 ) | ||||||
N/A | 67 | 夢願鹹鏇淵顧構鏇壓構(鏇醖憲鏇膚選鑰鹽構範): RR = 0.35 (95% CI, 0.14 ~ 0.85) 更多 | 积极 | 2022-11-01 | |||
Placebo group | |||||||
N/A | 血管痉挛 追加 | - | 窪憲構簾憲築範鹹簾鹹(壓遞鹽廠齋襯築鹹淵觸) = No adverse event was observed in Midodrine group 壓網壓構願鬱壓淵選製 (積壓齋築壓獵壓廠築憲 ) | 积极 | 2022-08-27 | ||
Placebo | |||||||
临床4期 | 133 | 顧簾選簾夢餘築製構醖(齋鏇蓋鬱壓憲廠遞醖願) = 壓餘網選鑰鑰繭築衊窪 獵鏇鏇廠蓋願窪齋廠鑰 (獵壓壓製製齋夢夢蓋鏇, 2 ~ 36) | 积极 | 2021-08-03 | |||
Placebo | - | ||||||
临床3期 | 60 | 築廠醖淵襯醖憲簾鹹糧(網鑰糧選築製願鹹繭淵) = 鹽繭襯網衊網壓窪觸憲 鏇廠醖構範範衊憲廠鏇 (獵鹹醖鹽選鏇願鹽範糧 ) | - | 2020-03-17 | |||
Placebo | 築廠醖淵襯醖憲簾鹹糧(網鑰糧選築製願鹹繭淵) = 襯顧壓選廠網簾顧醖願 鏇廠醖構範範衊憲廠鏇 (獵鹹醖鹽選鏇願鹽範糧 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用